BACKGROUND: The ongoing effort to prevent dialysis-related amyloidosis (DRA) has been hampered by lack of any way to measure DRA's severity. Yet, such measurement is essential for assessing the effect of DRA treatment. Accordingly, we developed a scoring system focused on the physical manifestations of DRA. METHODS: Forty-four patients on maintenance hemodialysis with DRA, and 96 without it, were enrolled. The SF-36v2 Health Survey ascertained whether patients experienced general bodily pain and/or physical dysfunction with any attendant specific pain (dysfunction). If so, the association of those conditions with a finding of DRA was analyzed-including laboratory and radiographic data-and a scoring system reflecting the extent of that dysfunction was devised using the significant variables in the multivariate analysis. RESULTS: Both dysfunction and general bodily pain were severe in patients with DRA. Presence of polyarthralgia, trigger finger, carpal tunnel syndrome (CTS), and dialysis-related spondyloarthropathy (DRS) were associated with that dysfunction after appropriate adjustments. The new scoring system used those four variables in the model, with a 3 given for polyarthralgia and DRS, and 2 for trigger finger and CTS (possible range 0-10). Based on the physical functioning score of SF-36v2, we categorized A-score into three stages: mild (A-score 3-4), moderate (5-7), and severe (8-10). The corresponding area under the receiver-operating characteristics curve for diagnosis of DRA was 0.9345 when we set the cutoff value as 4. CONCLUSION: This validated scoring system for quantitatively estimating the severity of DRA can serve as A useful measure in clinical practice.
BACKGROUND: The ongoing effort to prevent dialysis-related amyloidosis (DRA) has been hampered by lack of any way to measure DRA's severity. Yet, such measurement is essential for assessing the effect of DRA treatment. Accordingly, we developed a scoring system focused on the physical manifestations of DRA. METHODS: Forty-four patients on maintenance hemodialysis with DRA, and 96 without it, were enrolled. The SF-36v2 Health Survey ascertained whether patients experienced general bodily pain and/or physical dysfunction with any attendant specific pain (dysfunction). If so, the association of those conditions with a finding of DRA was analyzed-including laboratory and radiographic data-and a scoring system reflecting the extent of that dysfunction was devised using the significant variables in the multivariate analysis. RESULTS: Both dysfunction and general bodily pain were severe in patients with DRA. Presence of polyarthralgia, trigger finger, carpal tunnel syndrome (CTS), and dialysis-related spondyloarthropathy (DRS) were associated with that dysfunction after appropriate adjustments. The new scoring system used those four variables in the model, with a 3 given for polyarthralgia and DRS, and 2 for trigger finger and CTS (possible range 0-10). Based on the physical functioning score of SF-36v2, we categorized A-score into three stages: mild (A-score 3-4), moderate (5-7), and severe (8-10). The corresponding area under the receiver-operating characteristics curve for diagnosis of DRA was 0.9345 when we set the cutoff value as 4. CONCLUSION: This validated scoring system for quantitatively estimating the severity of DRA can serve as A useful measure in clinical practice.
Entities:
Keywords:
Amyloidosis; Clinical staging; Dialysis; Physical dysfunction; Scoring system
Authors: K Nokura; H Koga; H Yamamoto; A Kimura; H Tamai; S Yazaki; N Suzuki; S Miyazaki; T Niwa Journal: J Neurol Sci Date: 2000-09-15 Impact factor: 3.181
Authors: David C Seldin; Jennifer J Anderson; Vaishali Sanchorawala; Karim Malek; Daniel G Wright; Karen Quillen; Kathleen T Finn; John L Berk; Laura M Dember; Rodney H Falk; Martha Skinner Journal: Blood Date: 2004-05-20 Impact factor: 22.113
Authors: Giorgina Barbara Piccoli; Mammar Hachemi; Ida Molfino; Jean Philippe Coindre; Charles Boursot Journal: BMC Nephrol Date: 2017-09-06 Impact factor: 2.388